Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

personalized neoantigen plasmid DNA melanoma vaccine EVX-02

A plasmid DNA melanoma vaccine composed of DNA plasmid encoding multiple, melanoma patient-specific neoepitopes, which are highly immunogenic tumor associated antigens (TAAs), with potential immunostimulatory and antineoplastic activities. Upon intramuscular (IM) administration of personalized neoantigen plasmid DNA melanoma vaccine EVX-02, the plasmid DNA is taken up by antigen-presenting cells (APCs) and the expressed neoepitopes induce cytotoxic T-lymphocyte (CTL)-mediated immune responses against melanoma cells expressing these specific TAAs.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:DNA-based melanoma vaccine EVX-02
personalized melanoma vaccine EVX-02
plasmid DNA melanoma vaccine EVX-02
Code name:EVX 02
EVX-02
EVX02
melanoma vaccine EVX-02
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search